HER-2 positive

P2, N=100, Recruiting, Jeeyun Lee | N=50 --> 100

Present findings are from a small sample cohort and need further validation from a larger cohort. The online version contains supplementary material available at 10.1007/s13193-025-02427-0.

Nationwide real-world data demonstrate favorable survival outcomes following adoption of dual anti-HER2 therapy. While these findings are broadly consistent with the CLEOPATRA trial, the observational design does not allow direct assessment of equivalence between studies.

P1/2, N=90, Recruiting, Canwell Biotech Limited | Not yet recruiting --> Recruiting

Although HER2-targeted therapies, such as trastuzumab deruxtecan, have shown promising results in HER2-positive bladder cancer, optimal immunohistochemistry (IHC) scoring criteria for urothelial carcinoma remain unclear...Upper GI and breast scoring criteria yield divergent scores in a significant subset of urothelial carcinomas, potentially affecting eligibility for targeted therapy. Associations with histologic subtype and metastatic site support disease-specific diagnostic and therapeutic strategies.

Circulating tumor DNA-based minimal residual disease assays offer a promising tool for refining risk stratification and potentially guiding the extent of surgery and adjuvant therapy. These strategies represent a transformative movement toward biologically tailored, response-adapted, less invasive treatments for early breast cancer to optimize quality of life without compromising long-term outcomes.

P2, N=88, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jun 2026 --> Jun 2027

These findings suggest that disparities in outcomes persist despite financial coverage of high-cost therapies, indicating the influence of structural and geographic factors on cancer care. This study provides real-world evidence to inform policies aimed at reducing inequities in access and outcomes among patients with breast cancer in Chile.

The ADC showed no significant body weight loss or organ damage in mice, indicating good tolerability. These findings validate a modular strategy combining a Fab scaffold, enzymatic site-specific conjugation, and ABD-mediated half-life extension to generate potent, homogeneous ADCs and nominate T-Fab-ABD(H + L)-DM1 as a promising candidate for HER2-positive cancer therapy.

Trastuzumab rezetecan improved progression-free survival versus pyrotinib plus capecitabine and showed a distinct safety profile in patients with HER2-positive breast cancer, presenting as a potential new treatment option.

No significant interactions were observed by molecular subtype, nodal status, or grade, although a nonsignificant trend toward stronger iTIL effects appeared in luminal B tumors. AI-based TIL quantification thus provides independent prognostic information in high-risk luminal breast cancer.

P4, N=10, Recruiting, City of Hope Medical Center | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027